Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
Interventions: AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee

Conditions: Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions: TRX518; Biological
Lead sponsor: Leap Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Myeloid, Acute
Interventions: Decitabine, BI 836858; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 4
States / cities: Jacksonville, Florida • Chicago, Illinois • Lake Success, New York + 1 more

Conditions: Brain Neoplasms, Neuroblastoma
Interventions: phenylbutyrate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HPV-Related Carcinoma
Interventions: IBRX-042; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 2
States / cities: El Segundo, California • Houston, Texas

Conditions: Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
Interventions: Vorinostat (SAHA), Velcade (PS-341, Bortezomib); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Solid Tumors
Interventions: CEP-37440; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: BT062; Drug
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more

Conditions: Multiple Myeloma
Interventions: CEP-18770, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Augusta, Georgia • Lexington, Kentucky • Houston, Texas

Conditions: Advanced Solid Tumor, Advanced Solid Malignancies
Interventions: PRJ1-3024; Drug
Lead sponsor: Zhuhai Yufan Biotechnologies Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • Cincinnati, Ohio + 3 more

Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: Everolimus, Nelarabine, Cyclophosphamide, Etoposide; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 29 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Colorectal Cancer (CRC), Gastric Cancer
Interventions: SC-007; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Rochester, Minnesota • St Louis, Missouri + 4 more

Conditions: Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
Interventions: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Leukemia
Interventions: Atuveciclib, BAY1143572; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more

Conditions: Maximum Tolerated Dose, Dose Escalation
Interventions: AD-NP1, Placebo; Drug
Lead sponsor: Arjun Deb, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumors
Interventions: BAY1436032; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Houston, Texas • Charlottesville, Virginia

Conditions: Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
Interventions: CB-03-10; Drug
Lead sponsor: Cosmo Technologies Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: California City, California • Colorado Springs, Colorado • New Haven, Connecticut + 3 more

Conditions: Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Blood Cancer, Hematological Malignancy
Interventions: MT-3724 Phase 1, MT-3724 Phase 2; Drug
Lead sponsor: Molecular Templates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Whittier, California • Jacksonville, Florida + 12 more

Conditions: Neoplasms
Interventions: Roniciclib (BAY1000394); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: St Louis, Missouri • Buffalo, New York • Cleveland, Ohio

Conditions: Neoplasms
Interventions: BI 754091; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Sarasota, Florida • Harvey, Illinois • Detroit, Michigan + 4 more

Conditions: Neoplasm
Interventions: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more

Conditions: Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions: BKM120, Trastuzumab, Capecitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more

Conditions: Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions: DCR-MYC; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Search by objective public record fields.

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy

IBRX-042 In Participants With HPV-Associated Tumors

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

A Study of SC-007 in Subjects With Advanced Cancer

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma